TEVA and IMRX Related Headlines
Go Back- Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug
- Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
- Immuneering doses first patient in phase 3 pancreatic cancer trial
- Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
- Immuneering reports 17.3-month survival in pancreatic cancer trial
- Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
- Immuneering reports Q1 2026 financial results and clinical updates
- Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
- Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
TEVA and IMRX Related Press Releases
Go Back- Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
- Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
- Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
- Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
- Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
TEVA and IMRX Related SEC Filings
Go Back- Form 10-Q Immuneering Corp For: Jun 30
- Form 8-K Immuneering Corp For: Aug 05
- Form SCHEDULE 13G Immuneering Corp Filed by: BlackRock, Inc.
- Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew
- Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew
- Form 4 Immuneering Corp For: Jun 23 Filed by: Zeskind Benjamin J.
- Form 4 Immuneering Corp For: Jun 15 Filed by: Hall Brett Matthew
- Form 8-K Immuneering Corp For: Jun 11
- Form 4 Immuneering Corp For: Jun 11 Filed by: Schall Thomas J.
- Form 4 Immuneering Corp For: Jun 11 Filed by: HAUSMAN DIANA
- Form 4 Immuneering Corp For: Jun 11 Filed by: CARPENTER ROBERT J
- Form 4 Immuneering Corp For: Jun 11 Filed by: KEATING LAURIE
- Form 4 Immuneering Corp For: Jun 11 Filed by: Feinberg Peter
- Form 8-K Immuneering Corp For: Jun 11
- Form 8-K Immuneering Corp For: Jun 01
- Form 10-Q Immuneering Corp For: Mar 31
- Form 8-K Immuneering Corp For: May 15
- Form DEFA14A Immuneering Corp
- Form DEF 14A Immuneering Corp For: Apr 20
- Form 4 Immuneering Corp For: Mar 13 Filed by: Neufeld Leah R
- Form 10-K Immuneering Corp For: Dec 31
- Form 8-K Immuneering Corp For: Mar 06
- Form 4 Immuneering Corp For: Feb 03 Filed by: Bookman Michael
- Form 4 Immuneering Corp For: Feb 03 Filed by: Brakewood Harold Eugene
- Form 4 Immuneering Corp For: Feb 03 Filed by: Hall Brett Matthew
- Form 4 Immuneering Corp For: Feb 03 Filed by: Matushansky Igor
- Form 4 Immuneering Corp For: Feb 03 Filed by: Morales Mallory
- Form 4 Immuneering Corp For: Feb 03 Filed by: Neufeld Leah R
- Form 4 Immuneering Corp For: Feb 03 Filed by: Zeskind Benjamin J.
- Form SCHEDULE 13G/A Immuneering Corp Filed by: Zeskind Benjamin J.
- Form 4 Immuneering Corp For: Jan 16 Filed by: Brakewood Harold Eugene
- Form 4 Immuneering Corp For: Jan 15 Filed by: Schall Thomas J.
- Form 4 Immuneering Corp For: Jan 15 Filed by: Hall Brett Matthew
- Form SCHEDULE 13G/A Immuneering Corp Filed by: Empery Asset Management, LP
- Form 4 Immuneering Corp For: Jan 13 Filed by: Neufeld Leah R
- Form 4 Immuneering Corp For: Jan 12 Filed by: Feinberg Peter
- Form 8-K Immuneering Corp For: Jan 07
- Form 4 Immuneering Corp For: Jan 01 Filed by: KEATING LAURIE
- Form 4 Immuneering Corp For: Jan 01 Filed by: Feinberg Peter
- Form 10-Q Immuneering Corp For: Sep 30
- Form 8-K Immuneering Corp For: Nov 12
- Form SCHEDULE 13G Immuneering Corp Filed by: Empery Asset Management, LP
- Form SCHEDULE 13G Immuneering Corp Filed by: FMR LLC
- Form 4 Immuneering Corp For: Oct 03 Filed by: Feinberg Peter
